Patients on warfarin should not use over-the-counter Miconazole oral gel (Daktarin)

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Miconazole oral gel indicated for first-line treatment for localised or mild oral candida (oral thrush) infection in children (aged over 4 months) and adults.

Two miconazole oral gel products are authorised in the UK:

  • Daktarin Oral Gel is classified as a prescription-only medicine (POM)

  • Daktarin Oral Gel Sugar Free 2% is classified as a pharmacy (P) medicine available without prescription but only from pharmacies, supplied by or under the supervision of a pharmacist.

Warfarin an oral anticoagulant indicated for prophylaxis of thromboembolic events. Daily dose depends on individual requirements and patients receiving therapy require regular coagulation tests.

The antifungal drug miconazole inhibits several P450 isozymes, including CYP2C9, which heightens the anticoagulant effect of warfarin leading to an increase in international normalised ratio (INR) values and subsequent bleeding complications. The potential for an interaction between miconazole and warfarin is documented in published literature, because of this, warnings are given in the Summaries of Product Characteristics about the potential for drug interactions between anticoagulants/warfarin and azole antifungals hence the anticoagulant effect should be carefully monitored.

In March 2016, the Medicines and Healthcare products Regulatory Agency (MHRA) received a Prevention of Future Deaths (regulation 28) report from a coroner regarding the death of a patient from intracerebral haemorrhage. The coroner raised concerns about the risks for a drug interaction between miconazole oral gel and warfarin, and a possible lack of awareness of the interaction among healthcare professionals.

In response to the report, MHRA initiated a review of available data about this interaction. The Commission on Human Medicines was asked to advise on whether measures were needed to minimise risk to patients. While further measures were being considered, an article in Drug Safety Update cautioned that miconazole oral gel is systemically absorbed and can enhance the anticoagulant effects of warf...

Recommended for you

  • Drug Updates
  • 1 comment

Patients on warfarin should not use over-the-counter Miconazole oral gel (Daktarin)

  • Drug Updates
  • no comment

Loperamide (Imodium): Overdoses of loperamide associated with risk of serious cardiovascular events

  • Drug Updates
  • 1 comment

Revised recommendations for use of adrenaline auto-injectors post European review

  • Drug Updates
  • 1 comment

Ibrutinib (Imbruvica▼): Reported cases of ventricular tachyarrhythmia and risk of hepatitis B reactivation and opportunistic infections

  • Drug Updates
  • 1 comment

Local and systemic administration of corticosteroids: risk of central serous chorioretinopathy

  • Drug Updates
  • 1 comment

Daclizumab (Zinbryta▼) in multiple sclerosis: Review patients for liver function currently on treatment

  • Drug Updates
  • 1 comment

Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): Risk of graft rejection

  • Drug Updates
  • 1 comment

Bendamustine (Levact): Increased mortality when used in combination treatment outside the approved indications

  • Drug Updates
  • 1 comment

Restrictions to manage the risk for misuse of pseudoephedrine and ephedrine to be continued

  • Drug Updates
  • no comment

Brimonidine gel (Mirvaso): Risk of cardiovascular events if applied to damaged skin

  • Drug Updates
  • 1 comment

Yellow Card Scheme Website: Report any side effects or safety concerns with e-cigarettes and e-liquids

  • Drug Updates
  • 1 comment

Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

  • Drug Updates
  • 1 comment

Finasteride 1 mg (Propecia): Reports of depression and suicidal thoughts in men

  • Drug Updates
  • 1 comment

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

  • Drug Updates
  • 1 comment

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

  • Drug Updates
  • 1 comment

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

  • Drug Updates
  • 1 comment

Pilot website to report adverse reactions of psychoactive substances

  • Drug Updates
  • 1 comment

Canagliflozin (Invokana▼): Increased risk of lower limb amputation

  • Drug Updates
  • 1 comment

Idelalisib (Zydelig▼): updated safety information on risk of infection

  • Drug Updates
  • 1 comment

Posaconazole (Noxafil): tablets and oral suspension not interchangable

  • Drug Updates
  • 1 comment

Levonorgestrel-containing emergency contraceptives: interaction with hepatic enzyme inducers

  • Drug Updates
  • 1 comment

Lonsurf ▼(trifluridine/tipiracil) approved for colorectal cancer chemotherapy

  • Drug Updates
  • 1 comment

Riociguat (Adempas) contraindicated in pulmonary hypertension associated with idiopathic interstitial pneumonias

  • Drug Updates
  • 1 comment

Rare reports of calciphylaxis in patients taking warfarin

  • Drug Updates
  • 1 comment

Suspected fatal drug interaction between citalopram and cocaine

  • Drug Updates
  • 1 comment

N-acetylcysteine interference with Siemens assays: false-low test results

  • Drug Updates
  • 1 comment

Epclusa (sofosbuvir/velpatasvir) approved for treatment of chronic HCV infection

  • Drug Updates
  • 1 comment

Duavive (conjugated oestrogens/ bazedoxifene) approved for treatment of menopausal symptoms

  • Drug Updates
  • 1 comment

Drug safety alert: Minimizing cardiac side effects associated with concomitant use of apomorphine and domperidone

  • Drug Updates
  • 1 comment

Drug safety update: Risk of progressive multifocal leukoencephalopathy with dimethyl fumarate (Tecfidera)